1. Cpca Cpd
2. Cyclopropane Carboxylic Acid
1. 1759-53-1
2. Carboxycyclopropane
3. Cyclopropylcarboxylic Acid
4. Cyclopropionic Acid
5. Cyclopropane Carboxylic Acid
6. Cpc-acid
7. Cyclopropanecarboxylicacid
8. Cyclopropyl Carboxylic Acid
9. Cyclopropane-carboxylic Acid
10. Nsc1112
11. Nsc-1112
12. 008803351s
13. Nsc 1112
14. Einecs 217-162-5
15. Cyclopropane Carboylic Acid
16. Brn 0969839
17. Ai3-30542
18. Mfcd00001287
19. Unii-008803351s
20. Cyclopropylmethanoic Acid
21. Cyclopropancarboxylic Acid
22. Cyclpropanecarboxylic Acid
23. Cyclopropan Carboxylic Acid
24. Cyclopropyl-carboxylic Acid
25. Wln: L3tj Avq
26. 2-cyclopropanecarboxylic Acid
27. 4-09-00-00003 (beilstein Handbook Reference)
28. 8 Olaparib Impurity 8
29. Chembl4649900
30. Dtxsid1040665
31. Chebi:23500
32. Cyclopropanecarboxylic Acid, 95%
33. Str00627
34. Zinc1587860
35. Stl168574
36. Akos000119770
37. Am83282
38. Cs-w018339
39. Db-016122
40. Ft-0624283
41. A812135
42. Cyclopropanecarboxylic Acid, Purum, >=98.0% (t)
43. Q-200907
44. Q2317381
45. F2191-0028
46. Z1258948161
47. Zpj
| Molecular Weight | 86.09 g/mol |
|---|---|
| Molecular Formula | C4H6O2 |
| XLogP3 | 0.6 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 1 |
| Exact Mass | 86.036779430 g/mol |
| Monoisotopic Mass | 86.036779430 g/mol |
| Topological Polar Surface Area | 37.3 Ų |
| Heavy Atom Count | 6 |
| Formal Charge | 0 |
| Complexity | 73.6 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
BUILDING BLOCK
SUPPLIERS
CAS Number : 1759-53-1
End Use API :
End Use API : Buprenorphine, Naltrexone, Olaparib, Prazepam
About the Company : INVENTYS Research Company – India’s Leading CDMO of Actives, Advanced Intermediates, and Specialty Chemicals. A research-driven Exclusive Synthesis and CDMO company from India – w...
CAS Number : 1759-53-1
End Use API :
End Use API : Buprenorphine, Naltrexone, Olaparib, Prazepam
About the Company : Shree Ganesh Remedies is established Since 1995 with an aim to manufacture, supply and export best quality of Pharmaceutical-intermediates, Bulk drugs and Speciality Chemicals to cater ...
END USE APIs
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
SCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.
EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.
Medichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Reliable Spanish CDMO Delivering High-Quality APIs and Intermediates with Excellence, Flexibility, and Regulatory Compliance.
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
Cambrex is an innovative life sciences company with a refreshingly human approach.
RELATED INTERMEDIATES
